Gene transfer of somatostatin receptor type 2 by intratumoral injection inhibits established pancreatic carcinoma xenografts

World Journal of Gastroenterology

Volumn 11, Issue 4, 2005, Pages 516-520

  Du, Zhi Yong ^a   Qin, Ren Yi ^a   Xia, Wei ^a   Tian, Rui ^a   Kumar, Manoj ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Pancreatic cancer; Somatostatin receptor type 2; Transfection; Xenografts

Indexed keywords

LIPOFECTAMINE; SOMATOSTATIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSFECTION; GROWTH RATE; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INOCULATION; MOUSE; NICK END LABELING; NONHUMAN; NUDE MOUSE; PANCREAS CARCINOMA; PROMOTER REGION; PROTEIN EXPRESSION; SUBCUTANEOUS TISSUE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 13244291641     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i4.516     Document Type: Article

References (30)

1. Huizhen Y, Jiefu H. Pancreatic Carcinoma. 1st ed. Shanghai: Shanghai Science Technol Press 2001: 1-2
2. Vernejoul F, Faure P, Benali N, Calise D, Tiraby G, Pradayrol L, Susini C, Buscail L. Antitumor effect of in vivo somatostatin receptor subtype 2 gene transfer in primary and metastatic pancreatic cancer models. Cancer Res 2002; 62: 6124-6131
3. DiMaio JM, Clary BM, Via DF, Coveney E, Pappas TN, Lyerly HK. Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery 1994; 116: 205-213
4. Wang J, Lu XX, Chen DZ, Li SF, Zhang LS. Herpes simplex virus thymidine kinase and ganciclovir suicide gene therapy for human pancreatic cancer. World J Gastroenterol 2004; 10: 400-403
5. Hajri A, Wack S, Lehn P, Vigneron JP, Lehn JM, Marescaux J, Aprahamian M. Combined suicide gene therapy for pancreatic peritoneal carcinomatosis, using BGTC liposomes. Cancer Gene Ther 2004; 11: 16-27
6. Kanai F, Kawakami T, Hamada H, Sadata A, Yoshida Y, Tanaka T, Ohashi M, Tateishi K, Shiratori Y, Omata M. Adenovirus-mediated transduction of E.coli uracil phosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil. Cancer Res 1998; 58: 1946-1951
7. Motoi F, Sunamura M, Ding L, Duda DG, Yoshida Y, Zhang W, Matsuno S, Hamada H. Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus. Hum Gene Ther 2000; 11: 223-235
8. Ghaneh P, Greenhalf W, Humphreys M, Wilson D, Zumstein L, Lemoine NR, Neoptolemos JP. Adenovirus-mediated transfer of p53 and p16 (INK4a) results in pancreatic cancer regression in vitro and in vivo. Gene Ther 2001; 8: 199-208
9. Schally AV. Oncological applications of somatostatin analogues. Cancer Res 1988; 48(24 Pt 1): 6977-6985
10. Buscail L, Saint-Laurent N, Chastre E, Vaillant JC, Gespach C, Capella G, Kalthoff H, Lluis F, Vaysse N, Susini C. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res 1996; 56: 1823-1827
11. Klijn JG, Hoff AM, Planting AS, Verweij J, Kok T, Lamberts SW, Portengen H, Foekens JA. Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects. Br J Cancer 1990; 62: 627-630
12. Canobbio L, Boccardo F, Cannata D, Gallotti P, Epis R. Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014. Preliminary results of a pilot study. Cancer 1992; 69 648-650
13. Friess H, Buchler M, Beglinger C, Weber A, Kunz J, Fritsch K, Dennler HJ, Beger HG. Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer. Pancreas 1993; 8: 540-545
14. Raderer M, Hamilton G, Kurtaran A, Valencak J, Haberl I, Hoffmann O, Kornek GV, Vorbeck F, Hejna MH, Virgolini I, Scheithauer W. Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results. Br J Cancer 1999; 79: 535-537
15. Celinski SA, Fisher WE, Amaya F, Wu YQ, Yao Q, Youker KA, Li M. Somatostatin receptor gene transfer inhibits established pancreatic cancer xenografts. J Surg Res 2003; 115: 41-47
16. Delesque N, Buscail L, Esteve JP, Saint-Laurent N, Muller C, Weckbecker G, Bruns C, Vaysse N, Susini C. sst2 somatostatin receptor expression reverses tumorigenicity of human pancreatic cancer cells. Cancer Res 1997; 57: 956-962
17. Fisher WE, Wu Y, Amaya F, Berger DH. Somatostatin receptor subtype 2 gene therapy inhibits pancreatic cancer in vitro. J Surg Res 2002; 105: 58-64
18. Rochaix P, Delesque N, Esteve JP, Saint-Laurent N, Voight JJ, Vaysse N, Susini C, Buscail L. Gene therapy for pancreatic carcinoma: local and distant antitumor effects after somatostatin receptor sst2 gene transfer. Hum Gene Ther 1999; 10: 995-1008
19. Yang L, Chiang Y, Lenz HJ, Danenberg KD, Spears CP, Gordon EM, Anderson WF, Parekh D. Intercellular communication mediates the bystander effect during herpes simplex thymidine kinase/ganciclovir-based gene therapy of human gastrointestinal tumor cells. Hum Gene Ther 1998; 9: 719-728
20. Sturtz FG, Waddell K, Shulok J, Chen X, Caruso M, Sanson M, Snodgrass HR, Platika D. Variable efficiency of the thymidine kinase/ganciclovir system in human glioblastoma cell lines: implications for gene therapy. Hum Gene Ther 1997; 8: 1945-1953
21. Barba D, Hardin J, Ray J, Gage FH. Thymidine kinase-mediated killing of rat brain tumors. J Neurosurg 1993; 79: 729-735
22. Pages P, Benali N, Saint-Laurent N, Esteve JP, Schally AV, Tkaczuk J, Vaysse N, Susini C, Buscail L. sst2 somatostatin receptor mediates cell cycle arrest and induction of p27 (Kip1). Evidence for the role of SHP-1. J Biol Chem 1999; 274: 15186-15193
23. Verheul HM, Pinedo HM. The role of vascular endothelial growth factor (VEGF) in tumor angiogenesis and early clinical development of VEGF-receptor kinase inhibitors. Clin Breast Cancer 2000; 1 Suppl 1): S80-84
24. Sipos B, Weber D, Ungefroren H, Kalthoff H, Zühlsdorff A, Luther C, Török V, Klöppel G. Vascular endothelial growth factor mediated angiogenic potential of pancreatic ductal carcinomas enhanced by hypoxia: an in vitro and in vivo study. Int J Cancer 2002; 102: 592-600
25. Korc M. Role of growth factors in pancreatic cancer. Surg Oncol Clin N Am 1998; 7: 25-41
26. Arii S, Mori A, Uchida S, Fujimoto K, Shimada Y, Imamura. M. Implication of vascular endothelial growth factor in the development and metastasis of human cancers. Hum Cell 1999; 12 25-30
27. Qin RY, Fang RL, Gupta MK, Liu ZR, Wang DY, Chang Q, Chen YB. Alteration of somatostatin receptor subtype 2 gene expression in pancreatic tumor angiogenesis. World J Gastroenterol 2004; 10 132-135
28. Kumar M, Liu ZR, Thapa L, Qin RY. Antiangiogenic effects of somatostatin receptor subtype 2 on human pancreatic cancer xenografts. Carcinogenesis 2004; 25: 2075-2081
29. Kumar M, Liu ZR, Thapa L, Wang DY, Tian R, Qin RY. Mechanisms of inhibition of growth of human pancreatic carcinoma implanted in nude mice by somatostatin receptor subtype 2. Pancreas 2004; 29: 141-151
30. Kikutsuji T, Harada M, Tashiro S, Ii S, Moritani M, Yamaoka T, Itakura M. Expression of somatostatin receptor subtypes and growth inhibition in human exocrine pancreatic cancers. J Hepatobiliary Pancreat Surg 2000; 7: 496-503